STRC Long-Read Diagnostics 2025
The diagnostic pipeline for STRC is advancing faster than therapy. Three publications in 2025 push the needle.
Scientific Reports 2025: Targeted long-read nanopore sequencing using MinION plus long-range PCR. Specifically designed to detect heterozygous STRC deletions and distinguish STRC from the STRCP1 pseudogene (99.6% sequence identity). Standard short-read sequencing can’t reliably tell them apart. Long reads span the divergent regions and resolve ambiguity.
Molecular Genetics and Genomics 2025: Chinese population study. STRC variant spectrum in 1,015 SNHL patients. Population-specific data that helps with variant interpretation, especially for Asian populations.
Journal of Human Genetics 2025: Improved detection of complex rearrangements in the 15q15.3 region. This is where STRC lives, and the pseudogene makes structural variants particularly tricky to call.
For Misha: these tools could help with reclassification at HKCH. The November 2026 genetics panel needs the best available evidence. If we can get long-read confirmation of the variant’s pathogenicity, or at least rule out pseudogene interference in the original call, that strengthens the case.
The pseudogene problem has been the biggest diagnostic headache for STRC. These tools are finally solving it.
Connections
- STRC Gene Therapy — diagnostics precede therapy
- STRC Pseudogene Problem — the core challenge these tools address
- STRC Variant c.4976A>C — Misha — directly relevant to Misha’s diagnostic workup
- STRC E1659A Conservation and Reclassification — reclassification evidence
- STRC Gene — STRC genomic context